SRRKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scholar Rock Holding Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$40.24+0.34 (+0.85%)
Close on Oct 19, 2026
- Market cap
- $5.26B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -46.3% | -123.1% | |
| Return on assets | – | -29.6% | -86.0% | |
| Current ratio | – | 8.09 | 6.95 | |
| Debt to equity | – | 0.09 | 0.41 | |
| Net debt to EBITDA | – | 1.62× | 0.58× | |
| Interest coverage | – | -217.2× | -55.8× | |
| Capex to revenue | – | 26.5% | – | |
| Diluted shares | – | 31M | 115M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Scholar Rock generated $905.69M from operations and spent $7.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$905.69M
Used
$7.08M
Capital expenditure$7.08M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-405.2%
×Asset turnover0.10×
×Equity multiplier1.53×
=Return on equity, FY2022-62.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2022 | -405.2% | 0.10× | 1.53× | -62.2% |
| FY2021 | -700.5% | 0.05× | 1.60× | -60.9% |
| FY2020 | -561.5% | 0.05× | 1.56× | -46.3% |
| FY2019 | -248.9% | 0.11× | 1.72× | -46.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$377.94M
- Cash generatingOperating cash flow above zero-$300.04M
- Return on assets improvedROA up on the prior year-79.2% → -79.6%
- Earnings backed by cashOperating cash flow above net income-$300.04M vs -$377.94M
- Less leverageLong-term debt to assets fell10.6% → 24.7%
- Better liquidityCurrent ratio rose9.61 → 6.95
- No dilutionShare count did not rise100M → 115M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.00